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Rino Rappuoli is a graduate of Siena University, where
he also earned his PhD before moving to the Sclavo
Research Center, the Italian vaccine institute, also in
Siena. He then spent two years in the USA, mostly at
Harvard with John Murphy and Alwin Pappenheimer
working on a new diphtheria vaccine based on a
non-toxic mutant of diphtheria toxin which has since
become the basis for conjugate vaccines against
haemophilus, meningococcus, and pneumococcal
infections, before returning to the Sclavo Research
Center where he developed an acellular vaccine based
on a mutant pertussis toxin. With many achievements
in vaccine development to his credit, he is now Global
Head of Vaccines Research and Development for
Novartis Vaccines in Siena, and has most recently
pioneered reverse vaccinology, in which the genome
of the pathogen is screened for candidate antigenic
and immunogenic vaccine components. We spoke to
him about the potential for outbreaks of the kind we
are now seeing with Ebolavirus in West Africa, and
what can be done to prevent them.which emerged in 2003, there is no licensed vaccine forEbolavirus disease has been much in the news
recently because of the horrendous outbreak in
West Africa – but how many other rare, sporadic
but severe infections are there that pose an equal
threat?
Well, during the last few years, more or less with every
6 months to a year there has been a new outbreak of an
emerging infection. Examples are the influenza viruses -
for instance H1N1 in 2009, and H7N9 and H5N1 more re-
cently [1] - the MERS rotavirus in Saudi Arabia [2], and
Chikungunya virus in St Martin in 2013 [3], and of course
now Ebola virus [4]. So there are many rare but potentially
very dangerous diseases or emerging infections regularlyCorrespondence: rino.rappuoli@novartis.com
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unless otherwise stated.breaking out. Ebola virus is by far the most lethal that we
have now, but all of the others are very dangerous.I know that there are ’flu vaccines, but are there
licensed vaccines for any of the others?
The answer is no - there are no vaccines for SARS,
MERS, there is no licensed vaccine for Chikungunya,
there is no licensed vaccine for Ebola - so for most of
these diseases there are no vaccines, because they are
too rare to justify the economic investment.Is that the only difficultly, or are there other
difficulties in developing vaccines for these sorts of
diseases? I realise it may be impossible to generalise.
Most of the time we do have the technologies to make
these vaccines. I remember for example when SARS
came in 2003/2004 we made a vaccine pretty quickly
and brought it to the stage where it was ready to go to
phase 1, but when we got to phase 1 the disease had
gone away, there was no interest, no incentive to bring it
even to phase 1, so we dropped it. For Ebola I think that
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there was no market, no demand.Do you think this is going to have to change in
the light of what has happened with Ebola?
I hope that this humanitarian and health disaster is go-
ing to help us to become a little bit smarter in planning
the future. I see these emerging infectious diseases as a
constant threat. They pose a risk, just as in other areas
we have a risk of earthquakes, we have a risk when we
drive a car of car accidents, when we buy a house there
is a risk of burning the house, and so on - and for all of
those risks we prepare ahead of time. We have insurance
for cars or we have insurance for houses and we build
buildings that are earthquake-resistant. It looks as
though the only place where we are not able to make in-
vestments ahead of time is health - we always have to
wait for the disaster to happen and then we rush and
usually with the vaccine we come too late and when the
disease is no longer there then everyone forgets and we
go from one disaster to another.How forward-thinking do we need to be? - How
long does it actually take to develop a vaccine,
generally?
For a normal commercial vaccine the time is between 10
and 15 years. Under very accelerated circumstances, like
those we have now for Ebola, you can take advantage of
previous studies that have been done and try to rush the
development of the vaccine, but we do take risks with
safety and efficacy when we accelerate so much, so I think
we will be wise to develop those vaccines ahead of time.How much of a problem is viral mutation?
It depends on the virus, so for Ebola it is not a problem at
all, for MERS it does not seem to be a problem, for SARS
it does not seem to be a problem, for Chikungunya it does
not seem to be a problem. For influenza it is a problem
and for HIV it is a big problem, so it depends on the virus.What about the possibility, aired in the Press,
that Ebola might become transmissible in an
airborne form? Do you have any view on that
possibility?
I believe that it is extremely unlikely. This virus has been
there for a long time in the wild in Africa and it has
never done it. It has had many opportunities to do it. I
don’t think that a small exposure to mankind right now
is going to do it and the preliminary data from the gen-
etics and genomics of the virus show very good stability
so I don’t think this is a risk in the short term.So a little bit of good news. But you say one of
these diseases pops out about every six months.
Do you expect that we’ll be continuing to see
emerging infections we haven’t seen before?
Oh yes, I believe that in six months we will have a new
emerging disease. Hopefully the Ebola outbreak will be
under control. It will not be in the news and there will
be other news about another emerging infection and we
will rush into the new one, and instead of doing that I
think it would be nice to be able to plan ahead of time. I
think we have technologies today by which we could
prepare multiple vaccine platforms that could be tested
for safety and efficacy against multiple diseases and
where you could plug in an antigen from a new emer-
ging infection quickly. We already effectively have this
for influenza virus, for which as the virus mutates each
year we just plug in the most prevalent haemagglutinin
variants to the existing vaccine platform. If the regula-
tory authorities could approve platforms suitable for use
against other pathogens – thus already of proven safety
and efficacy – we could have a way of being as ready as
possible for unexpected events.
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